Redeye recently initiated coverage of Curasight, a Danish biotech company offering a theranostics platform (therapy + diagnostics) in PET imaging and radioligand (local radiation) therapy based on the novel use of the versatile uPAR cancer biomarker. Analyst Fredrik Thor talks us through the investment case.